Guardant Health Appoints Former Dexcom CEO Kevin Sayer to Board and Names Robert Parks as CAO

Executive Summary

On November 3, 2026, Guardant Health, Inc. filed a Current Report on Form 8-K disclosing two key personnel additions approved by the Board of Directors on November 2, 2026:

1. Appointment of Director: Kevin R. Sayer was appointed to the Board as a Class II director with a term expiring at the 2029 Annual Meeting of Stockholders. The Board size was concurrently expanded from 10 to 11 directors.
2. Appointment of Principal Accounting Officer: Robert A. Parks was appointed as Chief Accounting Officer (CAO) and assumed the role of Principal Accounting Officer.

---

Key Details & Backgrounds

1. Kevin R. Sayer (Director)

• Industry Experience: Currently serves as Executive Chairman of Dexcom, Inc. (effective January 2026) and served as President and CEO of Dexcom from 2015 to January 2026. Previously served as CFO of Biosensors International Group and held executive roles at Specialty Laboratories and MiniMed.
• Compensation: Standard non-employee director compensation under the Company’s Eligible Director Compensation Program:
  • Initial Equity Award: Restricted Stock Units (RSUs) valued at $500,000, vesting one-third after one year and the remaining two-thirds across the following two years.
  • Cash Retainer: $60,000 annual cash retainer.
• Governance: Standard indemnification agreement entered; no Item 404(a) related-party transactions reported.

2. Robert A. Parks (Chief Accounting Officer & Principal Accounting Officer)

• Industry Experience: Most recently served as CAO of Fortrea Holdings Inc. (2024–2026). Prior CAO roles include SailPoint Technologies (2023–2024), NetApp, Inc. (2021–2023), and Syneos Health, Inc. (2018–2021), alongside leadership roles at IQVIA Holdings and beginning his career at Ernst & Young LLP.
• Compensation: Entitled to an annual base salary, annual incentive bonus eligibility, long-term RSU incentives under the 2023 Employment Inducement Award Plan, and standard corporate benefit plans.

---

Market and Trading Impact

• Significance: Low.
• Routine governance and executive appointments under Item 5.02. While adding seasoned commercial health tech leadership (Dexcom's former CEO) strengthens board oversight, this event carries no direct financial transaction or dilution in the immediate term.